Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Prior

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Heart, Lung & Circulation|November 7, 2021
Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure SnapshotChristianne Tan, Diem Dinh, Angela Brennan, et al.
Annals of the Rheumatic Diseases|April 1, 2019
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosisNava Ferdowsi, Molla Huq, Wendy Stevens, et al.
Heart, Lung & Circulation|May 4, 2020
The Effect of Transitional Care on 30-Day Outcomes in Patients Hospitalised With Acute Heart FailureAndrea Driscoll, Diem Dinh, David Prior, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Seminars in Arthritis and Rheumatism|April 17, 2024
Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosisJessica L Fairley, Dylan Hansen, Susanna Proudman, et al.
Internal Medicine Journal|September 29, 2023
Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue diseaseJessica L Fairley, Laura Ross, Andrew Burns, et al.
ACR Open Rheumatology|October 5, 2023
Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert ConsensusTatsuya Atsumi, Sang-Cheol Bae, Hong Gu, et al.
International Journal of Cardiology|January 3, 2015
The prognostic impact of diastolic dysfunction in patients with chronic heart failure and post-acute myocardial infarction: Can age-stratified E/A ratio alone predict survival?Marzia Rigolli, Andrea Rossi, Miguel Quintana, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Heart, Lung & Circulation|November 7, 2021
Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure SnapshotChristianne Tan, Diem Dinh, Angela Brennan, et al.
Annals of the Rheumatic Diseases|April 1, 2019
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosisNava Ferdowsi, Molla Huq, Wendy Stevens, et al.
Heart, Lung & Circulation|May 4, 2020
The Effect of Transitional Care on 30-Day Outcomes in Patients Hospitalised With Acute Heart FailureAndrea Driscoll, Diem Dinh, David Prior, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Seminars in Arthritis and Rheumatism|April 17, 2024
Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosisJessica L Fairley, Dylan Hansen, Susanna Proudman, et al.
Internal Medicine Journal|September 29, 2023
Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue diseaseJessica L Fairley, Laura Ross, Andrew Burns, et al.
ACR Open Rheumatology|October 5, 2023
Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert ConsensusTatsuya Atsumi, Sang-Cheol Bae, Hong Gu, et al.
International Journal of Cardiology|January 3, 2015
The prognostic impact of diastolic dysfunction in patients with chronic heart failure and post-acute myocardial infarction: Can age-stratified E/A ratio alone predict survival?Marzia Rigolli, Andrea Rossi, Miguel Quintana, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Pageof 7